From professional translators, enterprises, web pages and freely available translation repositories.
10 succinylacetone u succinylacetoacetate.
in patients with ht-1, these intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate.
Last Update: 2011-10-23
Usage Frequency: 2
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
f’pazjenti b’ht-1, dawn l-intermedji jinbidlu għal metaboliti tossiċi succinylacetone u succinylacetoacetate.
in patients with ht-1, these intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
succinylacetone m’għandux ikun osservat fl-awrina jew fil-plażma meta d-doża ta’ nitisinone tkun aġġustata kif suppost.
succinylacetone should not be detectable in urine or plasma when the nitisinone dose is properly adjusted.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
succinylacetone jinibixxi s-sintesi tal-passaġġ ta’ porphyrin li jwassal għall-akkumulazzjoni ta’ 5-aminolevulinate.
succinylacetone inhibits the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
jekk succinylacetone fl- awrina jkun jista’ jiġi osservat wara xahar mill-bidu tal-kura b’nitisinone, id-doża ta’ nitisinone għandha tiżdied għal 1.5 mg/kg ta’ piż tal-ġisem / kuljum, maqsuma f’2 dożi.
if urine succinylacetone is still detectable one month after the start of nitisinone treatment, the nitisinone dose should be increased to 1.5 mg/kg body weight/day divided in 2 doses.
Last Update: 2017-04-26
Usage Frequency: 5
Quality:
